Media Conference
The Latest Media Conference
Conference on FY2020.12 Financial Results
Date:
February 04, 2021
Presentations:
- Review of 2020 and General Overview of IBI 21
- Tatsuro Kosaka,
Chairman & CEO - FY2020 Consolidated Financial Overview (Core)
- Toshiaki Itagaki,
Executive Vice President & CFO - Overview of Development Pipeline
- Tetsuya Yamaguchi,
Senior Vice President, Head of Project & Lifecycle Management Unit - New Growth Strategy for 2030
- Dr. Osamu Okuda,
President & COO
Materials:
2020
-
Dec 02, 2020
- Chugai Digital Strategy Meeting
-
- CHUGAI DIGITAL VISION 2030
- Satoko Shisai, Vice President, Head of Digital & IT Supervisory Div.
- Innovation in the Drug Discovery Process Using AI
- Dr. Hiroyuki Tsunoda, Head of Discovery Technology Dept., Research Div.
- Utilization of Real World Data
- Dr. Nobuya Ishii, Head of Science & Technology Intelligence Dept., Project & Lifecycle Management Unit
- Digital Marketing Strategy
- Takato Shimauchi, Head of Customer Solution Dept., Marketing & Sales Div.
-
Oct 22, 2020
- 3Q Results (Jan - Sep 2020) Conference Call
-
- FY2020 3Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Head of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
-
Sep 29, 2020
- Chugai ESG Meeting
-
- Progress in sustainability-oriented management and strategies
- Motoo Ueno, Representative Director & Deputy Chairman
- Deep-dive theme 1: Sustainability-related Indicators
- Toshiaki Itagaki, Executive Vice President & CFO
- Deep-dive theme 2: Long-term Planning
- Shigehiro Yamada, Ph.D., Head of Sustainability Dept.
- Deep-dive theme 3: Examples of Shared Value Creation
- Keiji Kono, Senior Vice President,
In charge of External Affairs Dept. and Global Health Policy
-
Sep 14, 2020
- Information Meeting on ENSPRYNG® Subcutaneous Injection
-
- Product Overview of ENSPRYNG® Subcutaneous Injection 120 mg Syringe
- Katsuhiro Hara,
ENSPRYNG® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd. - Current Status of the Treatment for Neuromyelitis Optica Spectrum Disorders (NMOSD) and Expectations for ENSPRYNG
- Prof. Kazuo Fujihara, M.D.
Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine
-
Jul 27, 2020
- 2Q Results (Jan - Jun 2020) Conference Call
-
- Aiming to Achieve the Mid-term Business Plan “IBI 21”
- FY2020 Half Year Results - - Tatsuro Kosaka,
Chairman and CEO - FY2020 2Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Minoru Watanabe,
Vice President, Head of Project & Lifecycle Management Unit
- Aiming to Achieve the Mid-term Business Plan “IBI 21”
-
Apr 23, 2020
- 1Q Results (Jan - Mar 2020) Conference Call
-
- FY2020 1Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Head of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
-
Jan 30, 2020
- Media conference on FY 2019.12 Financial Results
-
- Mid-term Business Plan “IBI 21”
- 2019 Results and 2020 Strategic Policies - - Tatsuro Kosaka,
President and CEO - FY2019 Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
- Mid-term Business Plan “IBI 21”
2019
-
Dec 09, 2019
- Information Meeting on Antibody Engineering Technologies
-
- Chugai’s Strategy for Drug Discovery Research
- Junichi Nezu, PhD,
General Manager of Research Division
Chugai Pharmaceutical Co., Ltd. - Chugai’s Antibody Engineering Technologies for Innovative Drug Discovery
- Tomoyuki Igawa, PhD,
CEO and Research Head, Chugai Pharmabody Research Pte. Ltd.
-
Oct 24,2019
- 3Q Results (Jan - Sep 2019) Conference Call
-
- FY2019 3Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President, CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept
-
Sep 05, 2019
- Information Meeting on Rozlytrek®
-
- Product Overview of Rozlytrek®
- Yoshito Nakanishi,
Rozlytrek® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd. - From organ specific to gene specific cancer treatment
- Expectations on ROZLYTREK for NTRK Fusion-Positive Solid Tumors - - Takayuki Yoshino, MD, PhD
Director, Department of Gastroenterology and Gastrointestinal Oncology,
National Cancer Center Hospital East (NCCE), Japan
Co-principal investigator, GI-SCREEN-Japan
-
Jul 25, 2019
- Media Conference on FY2019 2Q Financial Results
-
- Aiming to Achieve the Mid-term Business Plan “IBI 21”
- FY2019 Half Year Results - - Tatsuro Kosaka,
President and CEO - FY2019 2Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
- Aiming to Achieve the Mid-term Business Plan “IBI 21”
-
Jul 04, 2019
- Information Meeting on FoudationOne® CDx
-
- 1. FoundationOne® CDx Cancer Genomic Profile Product Overview
- Kosuke Iijima, Department Manager of Foundation Medicine Business Dept., Foundation Medicine Unit
- 2. Cancer Genomic Medicine
- Clinical Implementation and Challenges - - Prof. Muto Manabu, Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University
-
Jun 18, 2019
- ESG Meeting
-
Motoo Ueno, Representative Director, Deputy Chairman
-
Apr 24, 2019
- 1Q Results (Jan - Mar 2019) Conference Call
-
- FY2019 1Q Consolidated Financial Overview
- Toshiaki Itagaki,
Executive Vice President & CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
-
Jan 31, 2019
- Information Meeting on FY 2018.12 Financial Results
-
- New Mid-term Business Plan “IBI 21”
- Tatsuro Kosaka,
President and CEO - FY2018 Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
2018
-
Nov 07, 2018
- Information Meeting on GAZYVA®
-
- 1. Product Overview of GAZYVA® Intravenous Infusion 1000 mg
- Naoko Oya, GAZYVA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. Pathology of Follicular Lymphoma and Clinical Trial Results of obinutuzumab
- Kiyohiko Hatake, M.D., Ph.D.
Deputy Director, Head of the Malignant Tumor and Hematologic Tumor Center at the International University of Health and Welfare, Mita Hospital, Japan
-
Oct 24, 2018
- 3Q Results (Jan - Sep 2018) Conference Call
-
- FY2018 3Q Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President & CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
-
Jul 26, 2018
- Media Conference on FY2018 2Q Financial Results
-
- Aiming to Achieve Mid-term Business Plan “IBI 18”
- FY2018 Half Year Results - - Tatsuro Kosaka,
President and CEO - FY2018 2Q Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
- Aiming to Achieve Mid-term Business Plan “IBI 18”
-
Jun 01, 2018
- Information Meeting on HEMLIBRA®
-
- 1. HEMLIBRA® Subcutaneous Injection Product Overview
- Hiroshi Motegi, HEMLIBRA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. Current Status of Hemophilia Treatment and Expectations for HEMLIBRA®
- Prof. Midori Shima, M.D., Ph.D.
Department of Pediatrics, Nara Medical University
-
Apr 12, 2018
- Information Meeting on TECENTRIQ®
-
- 1. TECENTRIQ® Intravenous Infusion 1200mg Product Overview
- Mikio Sakai, TECENTRIQ® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. The Anti-PD-L1 Antibody Tecentriq® Mode of Action and Future Outlook
- Hiroyoshi Nishikawa, M.D., Ph.D.
Department of Immunology, Nagoya University Graduate School of Medicine
Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center - 3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq®
- Yuichiro Ohe, M.D.
Deputy Director, Chief,
Division of Thoracic Oncology
National Cancer Center Hospital, Japan
-
Feb 01, 2018
- Media Conference on 2017.12 Financial Results
-
- Aiming to Achieve Mid-Term Business Plan “IBI 18”
-2017 Results and 2018 Outlook- - Tatsuro Kosaka, President, COO
- FY2017 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit
- Aiming to Achieve Mid-Term Business Plan “IBI 18”
2017
-
Oct 30, 2017
- CEO Meeting
-
- Drastic Changes in the Environment of the New Drug Creation and Challenges Facing Japan’s Pharmaceutical Industry
- Chairman and CEO Osamu Nagayama
-
Jul 27, 2017
- Media Conference on FY2017 2Q Financial Results
-
- FY2017 2Q Consolidated Financial Overview
- Yoshio Itaya,
Executive Vice President, CFO - Overview of Development Pipeline
- Yasushi Ito,
Senior Vice President, Head of Project & Lifecycle Management Unit
-
Feb 01, 2017
- Media Conference on 2016.12 Financial Results
-
- Mid-Term Business Plan “IBI 18”
-2016 Results and 2017 Outlook- - Tatsuro Kosaka, President, COO
- FY2016 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit - Reorganization to Provide a New Solution
- Susumu Kato, Senior Vice President,
General Manager of Marketing & Sales Div.
- Mid-Term Business Plan “IBI 18”
2016
-
Jul 21, 2016
- Media Conference on FY2016 2Q Financial Results
-
- FY2016 2Q Consolidated Financial Overview
- Yoshio Itaya,
Executive Vice President CFO - Overview of Development Pipeline
- Minoru Watanabe,
Associate Vice President
Deputy General Manager of Research Division
-
May 19, 2016
- Joint Press Conference by Osaka University and Chugai Pharmaceutical Co., Ltd.
-
- Outline of the Comprehensive Collaboration Agreement between Osaka University and Chugai Pharmaceutical Co., Ltd.
- Executive Vice President of Research and Risk Management, Osaka University
Yasushi Yagi - Outline of Comprehensive Collaboration with IFReC
- CHUGAI PHARMACEUTICAL CO., LTD.
Executive Vice President
Yutaka Tanaka
-
Apr 05, 2016
- Information Meeting on Bonviva®
-
- 1. Product Overview of Bonviva® Tablet
- Takeshi Sakaguchi
Bonviva® Product Manager
Chugai Pharmaceutical Co., Ltd. - 2. Bonviva® Tablet: Clinical Utility and Our Expectation
- Hiroshi Hagino, M.D., Ph.D., Professor
School of Health Science
Tottori University Faculty of Medicine, Japan
- Presentation [PDF 3.2MB]
- Webcast(END)
-
Jan 28, 2016
- Media Conference on 2015.12 Financial Results
-
- New Mid-Term Business Plan "IBI 18"
- Tatsuro Kosaka, President, COO
- FY2015 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President
2015
-
Jul 23, 2015
- Media Conference on FY 2015.12 2Q Financial Results
-
- FY2015 2Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President
-
Apr 02, 2015
- Information Meeting on ZELBORAF®
-
- 1. Overview of ZELBORAF®
- Takahiro Mizui
ZELBORAF® Lifecycle Leader
CHUGAI PHARMACEUTICAL CO., LTD. - 2. cobas® BRAF V600 Mutation Test
- Toru Ogawa
Manager, Molecular Diagnostics
Roche Diagnostics K.K. - 3. ZELBORAF® tablet Postmarketing safety measures
- Shin Yoshida
Pharmacovigilance Department
CHUGAI PHARMACEUTICAL CO., LTD. - 4.Overview of melanoma and clinical trials of vemurafenib
- Naoya Yamazaki, M.D., Ph.D.
Chief, Dept. of Dermatologic Oncology
National Cancer Center Hospital, Japan
- Presentation [PDF 2.2MB]
- Webcast(END)
-
Jan 28, 2015
- Media Conference on 2014.12 Financial Results
-
- Aiming to Become a Top Pharmaceutical Company
- Tatsuro Kosaka, President, COO
- FY2014 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President,
Head of Project & Lifecycle Management Unit